Biogen is committed to meeting all global transparency requirements, including the Physician Payments Sunshine Act in the United States and the European Federation of Pharmaceutical Industries and Associations (EFPIA) Disclosure Code in the European Union. As is our obligation, we record all transfers of value to healthcare professionals and organizations and report pursuant to the applicable local codes and laws. We take care to ensure that the data that we submit is as detailed, comprehensive and clear as possible. This information is an important part of our ongoing collaboration with the healthcare community. Ultimately, the data we submit today can benefit patients in the future.

In the United States

The Physician Payments Sunshine Act was passed in March 2010 as part of the Patient Protection and Affordable Care Act in an effort to build transparency into the relationships between physicians and teaching hospitals with the healthcare industry, including the manufacturers of drugs, devices and medical supplies. The act requires manufacturers such as Biogen to report payments and other transfers of value made to U.S. healthcare professionals (HCPs) and healthcare organizations (HCOs) to the federal government. 

Biogen is committed to capturing comprehensive data to meet our obligation. As is required, we must report payments and in-kind items such as food, reprints and travel costs, regardless of the monetary value.

Accessing the data
The Centers for Medicare & Medicaid Services (CMS) has been charged with implementing the Physician Payments Sunshine Act. All data is collected and made publicly accessible via CMS’s Open Payments Program.

In the European Union

As a member of EFPIA, Biogen endorses the EFPIA Disclosure Code, a set of guiding principles that requires pharmaceutical companies to publicly disclose transfers of value made to European HCPs and HCOs.

In response to the growing public demand for transparency and to address the EFPIA Disclosure Code, Biogen has launched a program to ensure that it is able to collect transfers of value to European HCPs and HCOs beginning in January 2015 and report this information publicly by June 2016.